Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Jermaine Coward1, Hagen Kulbe1, Probir Chakravarty2, David Leader1, Vessela Vassileva1, D. Andrew Leinster1, Richard Thompson1, Tiziana Schioppa1, Jeffery Nemeth4, Jessica Vermeulen5, Donal J. Brennan7, Iain A. McNeish1, and Frances R. Balkwill1

Abstract

Purpose: We investigated whether inhibition of interleukin 6 (IL-6) has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network.

Experimental Design: We combined preclinical and in silico experiments with a phase 2 clinical trial of the anti-IL-6 antibody siltuximab in patients with platinum-resistant ovarian cancer.

Results: Automated immunohistochemistry on tissue microarrays from 221 ovarian cancer cases showed that intensity of IL-6 staining in malignant cells significantly associated with poor prognosis. Treatment of ovarian cancer cells with siltuximab reduced constitutive cytokine and chemokine production and also inhibited IL-6 signaling, tumor growth, the tumor-associated macrophage infiltrate and angiogenesis in IL-6–producing intraperitoneal ovarian cancer xenografts. In the clinical trial, the primary endpoint was response rate as assessed by combined RECIST and CA125 criteria. One patient of eighteen evaluable had a partial response, while seven others had periods of disease stabilization. In patients treated for 6 months, there was a significant decline in plasma levels of IL-6–regulated CCL2, CXCL12, and VEGF. Gene expression levels of factors that were reduced by siltuximab treatment in the patients significantly correlated with high IL-6 pathway gene expression and macrophage markers in microarray analyses of ovarian cancer biopsies.

Conclusion: IL-6 stimulates inflammatory cytokine production, tumor angiogenesis, and the tumor macrophage infiltrate in ovarian cancer and these actions can be inhibited by a neutralizing anti-IL-6 antibody in preclinical and clinical studies. Clin Cancer Res; 17(18); 6083–96. ©2011 AACR.

Introduction

Interleukin-6 (IL-6) has tumor-promoting actions on both malignant and stromal cells in a range of experimental cancer models (1–5). It also is a downstream effector of oncogenic ras (6) and has been implicated as an important part of the cytokine network in several human cancers, including serous and clear cell ovarian cancer (7, 8), multiple myeloma (9), Castleman’s disease (10), and hepatocellular carcinoma (11).

In ovarian cancer, there is preclinical evidence that IL-6 enhances tumor cell survival and increases resistance to chemotherapy via JAK/STAT signaling in tumor cells (12) and IL-6 receptor alpha transsignaling on tumor endothelial cells (13). In addition, IL-6 has proangiogenic properties (14), and regulating immune cell infiltration, stromal reaction, and the tumor-promoting actions of Th17 lymphocytes (15). In patients with advanced disease, high plasma levels of IL-6 correlate with poor prognosis (16, 17), and elevated levels are also present in malignant ascites (18). Some ovarian cancer cell lines constitutively secrete IL-6, and its production is enhanced when these cells are cocultured with other cells from the ovarian cancer microenvironment (7, 19, 20). We have found that this IL-6 is part of a malignant cell autocrine cytokine network in ovarian cancer cells (7). This network involves coregulation of the cytokines TNF-α and IL-1β, CCL2, CXCL12, and VEGF and has paracrine actions on angiogenesis in the tumor microenvironment.

Collectively, these data led to the hypothesis that IL-6 antagonists may have therapeutic activity in patients with...
as interleukin 6 (IL-6) is a major mediator of cancer-related inflammation, we investigated the therapeutic potential of IL-6 inhibition in ovarian cancer. The anti-IL-6 antibody siltuximab inhibited IL-6 signaling in ovarian cancer cells, with therapeutic effects in xenograft models, accompanied by reductions in angiogenesis and macrophage infiltration. In a phase 2 clinical trial in 18 women with platinum-resistant ovarian cancer, single agent siltuximab was well tolerated and had some therapeutic activity. Four patients had stable disease for 6 months or more, with reductions in plasma in the macrophage chemokines CCL2, CXCL12, and the angiogenic factor VEGF. Further clinical trials of siltuximab in ovarian cancer are indicated, with an emphasis on identifying subgroups of patients most likely to respond, especially as we found that some biopsies had high levels of IL-6 protein in the malignant cells and this was a poor prognostic sign.

Methods

Ethics statement

The phase 2 trial of siltuximab was approved by the appropriate UK regulatory authorities (MHRA reference 21313/0007; National Research Ethics Service reference 07/Q2803/30) and was conducted according to the Declaration of Helsinki. All animal experiments were approved by the local ethics review process of the Biological Services Unit, Queen Mary University of London and conducted according to the UKCCCR guidelines for the welfare and use of animals in cancer research (21).

Immunohistochemistry

Paraffin-embedded sections of diagnostic biopsies obtained from trial patients, tumor sections in the xenograft models and tissue microarrays (TMA) were stained with antibodies for IL-6 (Santa Cruz Biotechnology, sc-7920), CD68 (Dako, IR609), F4/80 (AbD Serotec, MCA497R), gp80 (Santa Cruz Biotechnology, sc-661), gp130 (Abcam, ab59389), Jagged-1 (R&D Systems, AF1277), Ki67 (Dako, M7240), and Tyr705 phospho-STAT3 (Cell Signaling, 9145). Slides were counterstained with haematoxylin. Frozen tumor sections were used for Ki67 and F4/80 immunohistochemistry in tumors from the TOV21G xenograft model. Negative controls of identical tissue sections were used whereby the primary antibody was omitted. The conditions used for staining with individual antibodies were in accord with manufacturers recommendations. In relation to the IL-6 staining, antigen retrieval was carried out in citrate buffer (Vector). IL-6 expression (Santa Cruz Biotechnology, sc-790, 1:50 dilution) was localized with diaminobenzidine.

Tissue microarray and automated analysis of immunohistochemistry

Seventy-six paraffin-embedded tumor specimens from a previously described cohort (22) were used for TMA construction as previously described (23). The TMA was constructed using a manual tissue arrayer (MTA-1, Beecher Inc.) and consisted of 4 cores per patient. Two 1.0 mm cores were extracted from each donor block and assembled in a recipient block. Two cores were taken from 2 different blocks for each tumor. There was an excellent correlation between cores (Spearman’s $r$, 0.88, $P < 0.001$ for IL-6), suggesting no difference between blocks. Recipient blocks were limited to approximately 100 cores each.

A second prospectively collected cohort of 134 ovarian cancer patients was used for validation (24). The Aperio ScanScope XT Slide Scanner (Aperio Technologies) system was used to capture whole slide digital images with a $\times 20$ objective. TMA slides were dearrayed to visualize individual cores, using Spectrum (Aperio). Genie histology pattern recognition software (Aperio) was used to identify tumor from stroma in individual cores and a color deconvolution algorithm (Aperio) was used to quantify tumor specific and stromal expression of IL-6, gp80, and gp130. For full-face sections, a region of interest was manually selected at low power (×5), 20 random HPFs were then generated using R software (www.r-project.org). Ten HPFs were then selected for analysis based on the quantity of tumor within the HPF and the absence of necrotic tissue and staining artefact. The output for the algorithm was intensity (measured on a scale of 0–255) and positivity (measured as the number of positive pixels/mm$^2$), which were combined to produce a tumor and stromal autoscore. Mean values were used for all tumors.

Cell culture

All glassware used for cell culture was baked at 220°C for 12 hours to remove contaminating endotoxin. All medium and culture reagents were prepared at Cancer Research UK Clare Hall, South Mimms, United Kingdom. Ovarian cancer cell lines (25) were grown in a humidified atmosphere at 37°C and 5% CO$_2$ in either endotoxin-free
RPIMI medium (IGROV-1, TOV11D, and TOV21G) or endotoxin-free Dulbecco's Modified Eagle's Medium (DMEM; SKOV-3) supplemented with 10% FBS (Autogen Bioclear) and passed twice weekly. Cell lines were regularly tested for mycoplasma infection and authenticated using 16 loci short-tandem repeat verification (LGC Standards).

**Siltuximab treatment of cells**
After overnight culture, cells were fed with medium containing siltuximab or isotype control IgG at 10, 25, 50, and 100 μg/mL in triplicate. Cells were re-fed with the appropriate antibody on days 4 and 7, and counted using a Vi-cell cell counter (Beckman Coulter) on days 4, 7, and 11 after typosinization and resuspension in 300 μL RPMI. Supernatants were collected on day 4 for cytokine analysis using MSD and ELISA assays (see below).

**Immunoblotting**
Cell lysates (15 μg) were electrophoresed on an SDS 10% acrylamide gel and transferred to a nylon membrane. The membrane was blocked overnight (4°C in PBS with 0.1% Tween and 10% milk powder) and probed using anti-Jagged1 (R&D Systems, AF1277) or pSTAT3 (Cell Signaling, D3A7) antibodies. A horseradish peroxidase-conjugated secondary antibody was used for detection (1:5,000, room temperature, 1 hour). Antibody binding was detected using the Western Lighting Chemiluminescence kit (Perkin-Elmer Life Science). Protein concentration equivalence was confirmed after probing with anti-β-actin antibody.

**Flow cytometry**
Cells were resuspended in DMEM supplemented with 2% heat inactivated FBS and 0.01% NaN3 and incubated for 40 minutes on ice with phycoerythrin (PE)-conjugated mouse monoclonal antibodies against the transmembrane IL-6 receptors gp80 (BD Pharmingen; 551850), gp130 (Santa Cruz Biotechnology, sc-9994 PE), or isotype-matched control (Santa Cruz Biotechnology, sc-2866) at 40 to 200 μg/mL. Cells were washed and analyzed by flow cytometry on a FACScan flow cytometer using Cellquest software (BD Pharmingen).

**Growth of tumors in mice and bioluminescence imaging**
A total of 5 x 10⁶ luciferase-expressing IGROV-1-luc, TOV21G-luc, or TOV112D-luc cells were injected intraperitoneally (i.p.) into 20g 6 to 8 week-old female BALB/c nu/nu mice. These cell lines were generated as previously published (7). Mice were observed daily for tumor growth and killed if peritoneal swelling reached UK Home Office limits (20% increase in abdominal girth). Mice were injected i.p. with 150 μg/g ɑ-luciferin in 100 μL PBS and imaged as previously described (7).

**Quantification of tumor blood vessels**
To visualize the architecture of blood vessels, animals were anesthetized and injected with FITC-conjugated *Lycopersicon esculentum* lectin (tomato lectin; 100 μL, 2 mg/mL; Vector Laboratories) via the tail vein 3 minutes before animals were perfused with 4% paraformaldehyde under terminal anesthesia. Samples were processed and microvessel density was analyzed as outlined in (7).

**Serum processing and cytokine analysis in mouse models**
A total of 100 μL blood was taken from all mice via the tail vein before and 2 and 4 weeks after tumor cell injection. Samples were aliquoted and stored on ice for 1 to 2 hours before centrifugation at 13,200 rpm for 15 minutes at 4°C. Serum was then snap frozen and stored at −80°C. Cytokine analyses with ECL assays were done according to manufacturer's instructions (MSD human IL-6, TNF-α, IL-8, and VEGF multiplex microplate, N45CA-1; MSD murine IL-6, TNF-α, IFN-γ and VEGF, N45IB-1).

**Patients and siltuximab administration**
Between August 2007 and January 2009, 20 patients, median age 62.5 years, with platinum-resistant ovarian cancer, defined as radiological and/or CA125 progression within 6 months of prior platinum-based chemotherapy, were recruited into this open label phase 2 study. Two patients progressed rapidly following consent with symptomatic small bowel obstruction and did not receive any treatment. Patients were deemed evaluable if they received one dose of siltuximab, thus 18 were evaluable. Patients were required to have adequate bone marrow and organ function and a World Health Organisation (WHO) performance status of 0 to 2. Patients could not have had more than 3 prior platinum-containing treatment regimens. Of the 18 evaluable patients, 9 (50%) had received 2 prior lines of chemotherapy, while 6 (33%) had received 3 or more lines. Of the 18, 7 had received prior single agent liposomal doxorubicin for platinum-resistant disease. Seventeen of the evaluable patients had disease that was measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, whereas one had raised CA125 only. Full inclusion and exclusion criteria are found in Supplementary Table S1 and patient characteristics are detailed in Supplementary Table S2.

The trial was funded by the United Kingdom Medical Research Council and sponsored and monitored by Queen Mary University of London. Each patient provided written informed consent. The trial was registered with the European Union Clinical Trials database (EudraCT, reference 2006-005704-13). The trial was subject to a MHRA inspection in November 2008 with no critical findings. OrthoBiotec Oncology supplied siltuximab at no cost. Each cycle of treatment involved an infusion of siltuximab at 5.4 mg/kg (ideal body weight) every 2 weeks. This dosing schedule was chosen as it had been shown in previous studies to suppress CRP concentrations below the lower limit of quantification and was also used in phase 1 studies siltuximab and pharmacokinetic modeling in other malignancies (26, 27). The primary endpoint was the response rate to siltuximab in patients with...
platinum-resistant ovarian cancer, while the secondary endpoints were changes in IL-6 and IL-6 related cytokines in response to siltuximab treatment, and quality of life, as assessed by EORTC QLQ-C30 and OV-28 questionnaires. Toxicity was assessed before each siltuximab infusion and reported using Common Terminology Criteria for Adverse Events version 3. Disease was assessed by CT scan after 3 (12 patients) or 5 (6 patients) treatments and every 12 weeks thereafter, and by CA125 measurement, conducted every 2 weeks. Best overall response was defined by combined RECIST/CA125 criteria (19). In addition, 14 patients also had [18F] FDG-PET imaging with their CT scans, which was analyzed as previously described (28).

**Blood sample collection from patients**

Blood was taken before each cycle of treatment for hematologic and biochemical indices, CRP and β2-microglobulin. During the first 3 treatments, blood was also taken on day 8 after each infusion. Blood was also taken before and 1 hour after each cycle of treatment and subsequently processed for plasma cytokine and chemokine analysis. Sampling was done 24 hours and 1 week after each of the first 3 infusions. All blood specimens were collected and handled by suitably trained, competent individuals. All samples were processed according to standard operating procedures and logged accordingly. In addition, freezer temperatures were monitored and logged on a daily basis.

Ten milliliter of blood was withdrawn from each patient and transferred into a 15 mL sterile, pyrogen-free falcon tube (BD Falcon) containing 300 units of heparin (CP Pharmaceuticals). The tubes were inverted gently several times to ensure thorough mixing, kept on wet ice and processed within 1 hour of collection by centrifugation at 3100 rpm or 2000 g for 10 minutes at 4°C. The plasma was then aspirated using sterile pastettes and 100 mL aliquoted into 10 × 1.5 mL cryovial tubes. Subsequently, all samples were snap frozen on dry ice before storage in a monitored −80°C freezer.

**Pharmacokinetic analysis**

Serum siltuximab concentrations were determined by an electrochemiluminescent-based immunoassay (MesoScale Discovery—MSD) method with a lower limit of quantification (LLOQ) of 0.045 μg/mL at a required dilution of 1:4. Validated assays were used to determine the concentration of siltuximab in the serum obtained before and 1 hour after each of the initial 3 infusions from all 18 evaluable patients.

**Electrochemiluminescence cytokine detection**

Cytokine concentrations were estimated by using MSD assays according to the manufacturer’s protocol. For IL-6, IL-8, TNF-α, and CCL2, after defrosting at 4°C, samples were centrifuged briefly at 2000 × g for 1 to 2 minutes at 4°C. These markers were prespecified in the trial protocol as there was prior evidence that they were coregulated with IL-6 (7). The calibrator standards, patient, and normal healthy control were incubated on the MSD microplates. Plates were washed and read using SECTOR Imager 2400 software (MSD). For plasma VEGF uncoated single-spot microplates were developed according to manufacturer’s instructions with calibrator standards, capture, and detection antibodies obtained from alternate sources (human VEGF DuoSet; DY293B). For human CXCL12 in plasma, a Quantikine ELISA kit (R&D Systems, DSA00) was used. Absorbance at 450 nm was measured and corrected at 570 nm in an Opsys MR plate reader (Dynex Technologies).

**Apoptosis marker**

M30 Apoptosense ELISA assays (PEVIVA AB) were done as previously described (29). The ELISA detects a neo-epitope mapped to positions 387 to 396 of a 21-kDa fragment of cytokeratin 18 that is only revealed after caspase cleavage of the protein and is postulated as a selective biomarker of apoptotic epithelial cell death (30). The assay has been subject to extensive validation (31).

**Gene set enrichment analysis using Metacore pathway and process gene set**

The microarray datasets GSE6008, GSE3149, and GSE9899 were downloaded from the GEO website [http://www.ncbi.nlm.nih.gov/geo]. Data were analyzed using Bioconductor 1.9 (http://bioconductor.org) running R 2.6.0 (32). Datasets GSE6008 and GSE3149 were merged to form one dataset. Probeset expression measures were calculated using the Affymetrix package’s Robust Multichip Average (RMA) default method (33). The function GeneSetTest from the limma package (34) was used to assess whether each sample had a tendency to be associated with an up or downregulation of members of the IL-6 pathway as defined by Metacore pathway analysis tool from Genego Inc., an integrated manually curated knowledge database. The function uses a Wilcoxon t test to generate P values. All samples were ranked on this enrichment, from the most significant to the least significant. The top and bottom 50 samples were extracted from the dataset and given the names high-IL-6 and low-IL-6, respectively. The same analysis was done in both datasets and then only common differential genes were used for downstream process enrichment. Differential gene expression was assessed between high IL-6 and low IL-6 pathway groups, using an empirical Bayes’ t test (limma package); P values were adjusted for multiple testing by using the Benjamini–Hochberg method (35). Any probe sets that exhibited an adjusted P value of 0.05 were called differentially expressed. The same analysis was done in both datasets and then only common differential genes were used for downstream process enrichment. Probes were divided into positive and negative fold change lists and used to determine enrichment using GeneGo pathways and processes within the Metacore pathway tool. The analysis employs a hypergeometric distribution to determine the most enriched gene set.
Heatmaps were drawn using expression data showing the probes that mapped to the biological processes of angiogenesis, apoptosis, cell cycle/proliferation and immune response/inflammation.

**Statistical analyses**

Statistical analysis was evaluated using the Mann–Whitney U test, unpaired t test and log-rank tests (GraphPad Prism version 5.0 software). Spearman’s ρ correlation was used to estimate the relationship between IL-6, gp80 and gp130 expression in the TMA (SPSS version 15.0 SPSS Inc.). \( P < 0.05 \) was considered statistically significant and all \( P \) values reported are 2-sided.

The clinical trial aimed to recruit 20 patients on the assumption that 16 would be evaluable for response. This sample size was determined on the assumption that a response rate of less than 10% would be of no further interest, whereas a clinical benefit rate of 20% or more would show evidence of activity meriting further study. The observation of one response in the first 16 patients limits to 5% the probability of failing to observe a true response rate of 10%.

**Results**

**High IL-6 expression by malignant ovarian cells is an indicator of poor prognosis**

Previous results suggest that high plasma IL-6 levels are associated with poor prognosis in ovarian cancer (16, 17) but there is no published information as to the source of this IL-6 in tumor biopsies from patients with ovarian cancer. We therefore stained for IL-6 and its transmembrane receptors in ovarian cancer biopsies in a 76 patient TMA (36) and also looked for any correlations with progression-free survival (PFS). IL-6 and gp80, gp130 receptors were all found on malignant and stromal cells (Fig. 1A). Automated algorithms were used to assess both malignant cell (tumor) and stromal compartments (Fig. 1B), and expression levels were quantified using an autoscore that combined both the intensity and density of positive pixels. IL-6 staining was seen in the malignant cells and infiltrating leukocytes, endothelial cells, and fibroblasts of the stromal areas. IL-6 staining was significantly higher in the malignant cell areas than the stromal areas \( (P < 0.001) \). In addition, high (defined as greater than median) IL-6
expression by malignant cells was significantly associated with shorter PFS in the whole cohort (P = 0.027; Fig. 1C), which was maintained when patients with serous carcinoma were analyzed separately (P = 0.020; Supplementary Fig. 1A). See Fig. 1A for an example of high and low levels of staining for IL-6 and its receptors in the biopsies. These data were confirmed in a separate TMA of 154 ovarian cancer patients (24). Although disease-free survival data were not available for the second cohort, high (again defined as greater than median) IL-6 expression positively associated with shorter overall survival (P = 0.015; Fig. 1D). However, neither IL-6 receptor expression nor stromal IL-6 associated with survival in these 2 cohorts (data not shown).

**Effects of siltuximab on human ovarian cancer cells in vitro**

As malignant cell IL-6 had a negative influence on ovarian cancer prognosis, and malignant cells showed the highest IL-6 protein staining in the biopsies, we assessed the activity of the monoclonal anti human IL-6 antibody siltuximab on 2 ovarian cancer cell lines that constitutively produced IL-6 (IGROV-1 and TOV21G) and 2 that did not (TOV112D and SKOV-3; Supplementary Fig. S1B). IL-6 production by TOV21G cells was greater than IGROV-1 cells (6,824 pg/10^6 cells/72 hours and 42 pg/10^6 cells/72 hours, respectively). Analysis of cell surface expression of IL-6 receptors gp80 and gp130 showed that 3 of the 4 cell lines (TOV21G, IGROV-1, SKOV-3) could potentially respond to exogenous IL-6 either bound to the cell surface or to soluble gp80 (Supplementary Fig. 1C). In vitro exposure of these ovarian cancer cells to siltuximab for 11 days had no effect on malignant cell growth even under serum-free conditions (data not shown). However, siltuximab inhibited constitutive release of IL-6 (Fig. 2A), and IL-6 signaling as measured by a reduction in phosphorylation of the IL-6–regulated transcription factor STAT3 (Fig. 2B). This suggests that there is autocrine stimulation of IL-6 production in these ovarian cancer cells that also express IL-6 receptors.

We also found inhibition of constitutive release of other cytokines that are part of an autocrine cytokine network in ovarian cancer cells (7), IL-1β, TNF-α, IL-8, and CCL2 (Fig. 2C), in the IL-6 secreting IGROV-1 and TOV21G cells, but there was no effect on IL-6 negative lines (data not shown). Recently, we found that constitutive production of the angiogenic factor Jagged1 in ovarian cancer cells was also associated with this autocrine cytokine network (Kulbe and colleagues, submitted for publication). Baseline Jagged1 expression was higher in the IL-6 secreting cell lines, and was stimulated by IL-6 and inhibited by siltuximab (Fig. 2D). This shows that an antibody that prevents the binding of constitutively produced IL-6 to IL-6 receptors that are also present on the ovarian cancer cells will inhibit the production of IL-6 and other cytokines and chemokines that are part of an autocrine cytokine network in the malignant cells. Although IL-6 inhibition impacts on constitutive production of other inflammatory and angiogenic mediators by ovarian cancer cells, it does not alter malignant cell growth or survival at least in tissue culture where there were no stromal influences.

**Actions of siltuximab on human ovarian cancer xenografts**

To investigate the influence of the microenvironment, we grew the ovarian cancer cells as intraperitoneal xenografts in nude mice and treated with siltuximab (20 mg/kg given twice-weekly i.p.). Four weeks of twice-weekly siltuximab injections significantly reduced growth (P < 0.05) of IGROV-1 tumors whether treatment started one (Fig. 3A left) or 14 days (Fig. 3A right) after tumor initiation, but had no impact on tumor growth in IL-6–negative TOV112D or SKOV-3 xenografts (data not shown). In the experiment where treatment was started 1 day after tumor cell injection, there was a 66% reduction in relative luminescence after 4 weeks treatment with siltuximab compared with a control IgG. In the experiment where treatment started 14 days after tumor cell injection, the siltuximab group had an 84% reduction in relative luminescence compared with control IgG. Siltuximab treatment of tumors from TOV21G cells, which produce higher concentrations of IL-6 in vitro than IGROV-1, produced consistent inhibition of tumor growth in 2 experiments, although this did not reach statistical significance (Supplementary Fig. S2A).

Siltuximab significantly reduced nuclear phospho-STAT3 expression in IGROV1 tumors compared with PBS or IgG, induced a significant reduction in human IL-6 (hIL-6) gene transcription after 4 weeks of treatment and had a strong inhibitory effect on Jagged1 protein and mRNA expression in IGROV1 tumors (Fig. 3B). Siltuximab also had significant inhibitory effects on tumor cell proliferation, F4/80+ macrophage infiltration and angiogenesis in both IGROV-1 and TOV21G tumors (Fig. 3C, Supplementary Fig. S2B), although differences were more pronounced in IGROV-1.

Human IL-6 was detected in serum of control mice 4 weeks after IGROV-1 tumors were established (Fig. 3D). In TOV21G-bearing mice, hIL-6 was detected earlier and at higher levels than in IGROV-1-bearing mice (Supplementary Fig. S2C). However, hIL-6 was detected in the serum of all siltuximab-treated mice after 2 weeks and levels increased one log further after 4 weeks (Fig. 3D). As hIL-6 mRNA was strongly decreased in tumors, this indicates that human IL-6 is sequestered by circulating antibody without a compensatory increase in tumor IL-6 production.

These results show that anti-IL-6 antibodies have greater activity when ovarian cancer cells are growing in a peritoneal environment.

**A phase 2 clinical trial of siltuximab in women with advanced platinum-resistant ovarian cancer**

In view of the data described above and previously published literature on IL-6 and ovarian cancer, we undertook a single arm, phase 2 clinical trial in patients with recurrent, platinum-resistant epithelial ovarian cancer.
cancer. Intravenous siltuximab (5.4 mg/kg ideal body weight) was administered every 2 weeks until disease progression and was well tolerated. Details of adverse events are in Supplementary Table S3. Nineteen patients had high-grade serous ovarian cancer and 1 patient had clear cell ovarian cancer.

Median PFS was 12 weeks and median overall survival (OS) was 49 weeks (Fig. 4A). Of the 18 evaluable patients, 16 have died, 1 patient is alive 127 weeks after trial entry, and 1 was lost to follow-up. By RECIST alone, there were no complete or partial responses. In 8 patients, however, stable disease was achieved, lasting 6 months or more in 4 patients. Disease progressed in 10 patients (PD). One patient had a partial response (PR) by combined RECIST/CA125 criteria (37), which was accompanied by a reduction in [18F] FDG uptake as detected by PET/CT imaging (Mean SUVMax baseline = 6.0; week 23 = 4.1; Fig. 4B). Increasing CA125 values declined in 3 other patients (Fig. 4C), while in patient 20, there was a significant change in CA125 doubling time (38) after commencing treatment. CA125 continued to increase in all patients who progressed by RECIST on treatment (data not shown). Pharmacokinetic analysis (Fig. 4D) indicated that the serum concentrations of siltuximab were at levels that had inhibited constitutive cytokine release by malignant cells in vitro (see Fig. 2).
Figure 3. Actions of siltuximab on intraperitoneal tumors formed from IGROV-1 cells. A, luciferase bioluminescence imaging was used to measure intraperitoneal tumor burden. Siltuximab (20 mg/kg twice weekly) treatment for 4 weeks started 1 day (left) or 14 days (right) after tumor cell injection, and significantly reduced tumor burden compared with IgG control (*, $P < 0.05$). All mice were killed after 4 weeks of treatment. B, effects of siltuximab on IL-6, phospho-STAT3, and Jagged1 expression in the IGROV-1 xenograft model following 4 weeks of siltuximab. The number of tumor cell nuclei showing positive staining for pSTAT3 were counted in 3 randomly selected areas per tumor section ($n = 3$) using a ×40 objective with approximately 500 nuclei counted per tumor (***, $P < 0.0001$). After 4 weeks of siltuximab treatment, there were also marked decreases in both human IL-6 and Jagged1 mRNA expression. RNA from 3 tumor samples in each group was used for this analysis. In addition, there was a reduction in Jagged-1 expression as detected by immunohistochemistry. Main photomicrographs taken with ×10 magnification lens, inset ×40. C, Ki67, F4/80, and tumor vasculature staining and quantification in IGROV-1 xenograft. Siltuximab significantly reduced cell proliferation compared with IgG control in IGROV-1 xenografts (***, $P < 0.001$). The proliferative index was calculated by estimating the percentage of tumor cells in 10 randomly selected areas per tissue section ($n = 3$) showing positive staining. Significant decreases in macrophage influx were seen with siltuximab compared with IgG control in the IGROV-1 xenograft (**, $P < 0.01$). The quantification was calculated by counting the number of F4/80+ cells from 10 randomly selected areas per tumor section ($n = 3$). Siltuximab also had a significant effect on tumor vasculature (*, $P = 0.0263$). The mean vascular area in each group was quantified by selecting 10 random areas per tumor section ($n = 3$). All data are representative of 2 independent experiments. D, human IL-6 was measured in serum of mice-bearing IGROV-1 xenografts. After 4 weeks, hIL-6 significantly increased with siltuximab treatment (**, $P = 0.01$). ND, not detected.
Cmax in cycle 3 was 59.1 μg/mL (95% CI: 45.0–110.6 μg/mL).

**Plasma biomarkers in response to siltuximab treatment**

We measured IL-6 and IL-6–regulated cytokines in patient plasma in an attempt to understand mechanisms of action of the anti-IL-6 antibody and identify potential biomarkers of response. Twenty-four hours after the first antibody infusion, there was a highly significant increase in measurable plasma IL-6, which continued after 6 weeks (Fig. 5A). Free IL-6 could not be detected, suggesting that the assay was detecting siltuximab-bound IL-6, in line with the xenograft data (See Fig. 3D) and observations in other clinical trials of siltuximab (39), antibodies to the IL-6 receptor or to TNF-α (40, 41).

There was a close correlation between baseline plasma IL-6 levels and serum levels of the inflammatory marker CRP ($r^2 = 0.74$, Spearman $\rho = 0.87$; Supplementary Fig. 3A). CRP levels declined in all patients after one dose of siltuximab (Fig. 5B) and fell below the LLOQ in 16 of the 18 evaluable patients. CRP remained suppressed for up to 19 weeks in patients who achieved SD, but was not maintained in 4 of 10 patients progressed during the first 3 to 5 treatments with siltuximab. There were no episodes of thrombocytopenia greater than grade 1 (platelet count 75–100 $\times 10^9/l$), but 2 patients experienced 1 episode each of grade 3 neutropenia (absolute neutrophil count 0.5–1.0 $\times 10^9/l$): each lasted less than 1 week and recovered spontaneously without growth factor support (Supplementary Table S3). There was a significant increase in Hb levels in the 14 patients who did not receive blood transfusions during the trial (Supplementary Fig. S3B). Plasma cytokine/chemokine levels were largely unchanged after three doses of siltuximab (Supplementary Fig. S3C). However, there was evidence that longer IL-6 blockade reduced plasma cytokine and chemokine levels. In the 4 patients who received at least 6 months treatment, there were significant declines in the IL-6–regulated chemokines CCL2, CXCL12, and the...
angiogenic factor VEGF. There was also a trend toward reduced IL-8 levels (Fig. 5C).

Although we could find no direct effects of siltuximab on ovarian cancer cells in vitro, potential effects on angiogenesis and macrophage infiltrate could have induced cell death in the tumor microenvironment. We therefore looked for evidence of apoptosis in patient plasma, measuring the cytokeratin 18 neoepitope M30, a marker of executioner caspase activation in epithelial cells (42). Median M30 levels increased significantly between baseline and 6 weeks (Fig. 5D).

**IL-6/IL-6 receptor expression in diagnostic biopsies from trial patients and an independent cohort**

Diagnostic tumor biopsies were available from 14 of the trial patients. Median tumor-specific IL-6 and gp130 expression was higher in SD/PR patients compared with PD patients (Supplementary Fig. S3D and E), although this difference did not reach statistical significance ($P = 0.103$ for IL-6). There were no differences in tumor-specific gp80 expression or stromal IL-6, gp80 or gp130 between the groups (data not shown).
Bioinformatics analysis of IL-6-linked pathways and processes in ovarian cancer biopsies

From the tissue culture, xenograft, and clinical trial data, we predicted that IL-6 is involved in the regulation of inflammatory cytokines, angiogenesis, and the infiltration of macrophages into the tumor microenvironment in ovarian cancers in which the malignant cells produce IL-6. To seek further confirmation of our findings, we studied human ovarian cancer biopsies for correlations between gene expression levels in the IL-6 pathway and expression of mediators that were downregulated by siltuximab in the clinical and preclinical experiments described above. We used gene expression data from 285 ovarian cancer biopsies from the Australian Ovarian Cancer Study (GSE9899; ref. 43) and ranked all samples for expression of IL-6 pathway genes (defined by the Metacore pathway tool). We then selected the 50 samples with the highest (high IL-6) and 50 with the lowest (low IL-6) levels of expression of genes in this pathway. Next, we generated a list of genes that were differentially expressed between the high IL-6 and low IL-6 samples [false discovery rate (FDR) < 0.05]. A similar process was done on a further 245 samples obtained by merging 2 other publicly available datasets (GSE6008 and GSE3149). All samples were used in each of the datasets for these analyses. We took forward genes that were differentially expressed in both analyses and found that high IL-6 pathway expression correlated positively with 4 of the genes whose levels were reduced by siltuximab treatment, namely CA125, IL-8, Jagged1 and CCL2 (all P < 0.003). There was also positive correlation with the macrophage cell surface markers CD14, CSF1R, and CD163 (Fig. 6A; all P < 0.0001). Using GSEA and Metacore, we found significant associations between high IL-6 pathway gene expression and the following pathways/processes: development blood vessel morphogenesis; regulation of angiogenesis; development role of IL-8 in angiogenesis; developmental VEGF signaling and activation; apoptosis/antiapoptosis, cell cycle/proliferation and immune response/inflammation (all P < 0.001; Fig. 6B). A full list of genes associated with high levels of IL-6 signaling pathway combining all information from the 3 datasets can be found in Supplementary Table S4.

Discussion

In this paper, we have shown how IL-6 production by malignant ovarian cancer cells stimulates inflammatory cytokine production, tumor angiogenesis, the tumor macrophage infiltrate and is associated with a poor prognosis. We also show that the anti-human IL-6 monoclonal antibody siltuximab, when given as a single agent, has some clinical activity in recurrent, platinum-resistant ovarian cancer. A total of eight patients achieved radiological disease response.

Figure 6. Bioinformatic analysis of IL-6 pathway gene expression in ovarian cancer biopsies. A, expression profile across the 50 highest and lowest ranked IL-6 pathway samples. RMA normalized expression values for the 7 genes were used to generate a heatmap. The colors indicate the expression value relative to the median expression value per gene in the dataset. Red indicates upregulation relative to median value and green indicates downregulation relative to the median value. The table shows the fold change and associated adjusted P value showing the difference between the top and bottom 50 IL-6 pathway ranked samples. B, process enrichment analysis of differentially expressed genes. Differentially expressed probes between the top 50 and bottom 50 IL-6 samples were selected based on meeting the criteria of FDR < 0.05. Probes were divided into positive and negative fold changes lists and used to determine enrichment using Genego processes within Metacore pathway. Processes were grouped based on annotated biological groups of angiogenesis, apoptosis, cell cycle/proliferation and immune response/inflammation. Heat maps were drawn for each biological process using the cluster package, using average linkage hierarchical algorithm to cluster the probes.
stabilization, which lasted 6 months or more in 4 cases. One of these 8 also had normalization of CA125 that lasted for 12 weeks, giving an overall partial response by combined RECIST/CA125 criteria. Combining results from clinical, preclinical and in silico analysis, we conclude that the mechanisms of action of anti-IL-6 in ovarian cancer are inhibition of an autocrine cytokine and chemokine network in the malignant cells that has paracrine actions on angiogenesis via inhibition of VEGF, Jagged1 and IL-8, and on the macrophage infiltrate via inhibition of the chemooxtratant CCL2. These conclusions were supported by gene expression analyses, in which IL-8, CCL2 and macrophage and angiogenesis markers all correlated significantly with highest levels of gene expression in the IL-6 pathway. There was no evidence of a direct growth inhibitory action of the anti-IL-6 antibody on ovarian cancer cells, effects on their survival were only evident in the presence of a tumor stroma suggesting that this was an indirect effect.

This is the first clinical study of anti-IL-6 therapy in ovarian cancer. Siltuximab has been evaluated recently in phase 2 trials in Castleman’s disease (26) and castration-resistant prostate cancer (39). In Castleman’s Disease, in which IL-6 is a key pathogenic driver, the objective response rate was 52%; by contrast, in prostate cancer, the response rate was 3.2%. Although the response rate here (3.6% by combined CA125/RECIST criteria) is modest, prolonged periods of disease stabilization were seen in women with recurrent, drug-resistant disease; and some evidence of activity on [18F]-FDG PET imaging. The median overall survival in this trial was similar to that seen in large randomized phase 3 trials of conventional chemotherapy, such as topotecan, liposomal doxorubicin, and gemcitabine, in platinum-resistant ovarian cancer (44, 45). However, larger randomized studies will be required to allow robust statistical conclusions to be drawn about the role of IL-6 inhibition in ovarian cancer treatment and to validate the biomarkers identified in our study.

At trial entry, there were no differences in clinical parameters between the patients who had stable disease and those who progressed through siltuximab treatment; all had platinum-resistant disease and the diagnostic biopsies from the stable disease patients tended to show higher expression of malignant cell IL-6, a feature that was associated with a shorter survival in the TMA cohorts. Nonetheless, it will be important in any future clinical trial to obtain new biopsies at time of trial enrolment to measure IL-6 activity by IHC and gene expression array and relate this to pretreatment plasma levels, especially as recent results suggest that tumor IL-6 expression is greater in recurrent ovarian cancer compared with matched primary disease (46).

Pharmacodynamic data from a phase 1 trial of siltuximab in metastatic renal cell cancer, as well as modeling data, suggest that the dose regime used in this trial (5.4 mg/kg every 2 weeks) should be sufficient to suppress CRP to below 5 mg/L in all patients with a baseline value more than 10 mg/L (27). Our results show that such suppression can be achieved by day 8 in platinum-resistant ovarian cancer patients. However, in 4 patients, whose mean baseline CRP was 50 mg/L, CRP suppression was transient and all 4 had progressive disease at first evaluation. Thus, it is possible that ovarian cancer patients with high baseline CRP values may require greater doses of anti-IL-6 antibodies for maximum pathway suppression.

In vitro, exposure of ovarian cancer cells that expressed IL-6 and its cell surface receptors to siltuximab inhibited constitutive release of IL-6 and other inflammatory cytokines. In xenograft experiments, siltuximab only inhibited growth of tumors that produced IL-6, and its actions were associated with a strong decline in human IL-6 and Jagged1 mRNA. As we did not have a mouse phenocopy of siltuximab and the anti-human IL-6 antibody does not neutralize murine IL-6, we could not fully recreate the effects of an anti-IL-6 antibody in a microenvironment where malignant cells and stroma are syngeneic. However, these experiments did show that plasma levels of human IL-6 in the nude mice were determined by both the inherent ability of the malignant cells to produce IL-6 and the tumor burden.

The majority of the work in this paper relates to high-grade serous ovarian cancer. However, more recently, we have found that clear cell ovarian cancer is characterized by specific overexpression of an IL-6-STAT3-HIF pathway (8). Treatment of 2 patients with the multireceptor tyrosine kinase inhibitor sunitinib induced changes in CA125 and FDG uptake that were maintained for 20 months in 1 of 2 patients. The TOV21G cell line used in our study comes from a clear cell carcinoma (25) and one of the patients in the trial was also diagnosed as clear cell carcinoma. This patient also had the highest pretreatment levels of both IL-6 (20.1 pg/mL) and CRP (69 mg/L). Further studies in clear cell carcinoma specifically are required to investigate the role of IL-6 in this ovarian cancer subtype.

Our results show that IL-6 stimulates inflammatory cytokine production, tumor angiogenesis and the tumor macrophage infiltrate in ovarian cancer and these actions can be inhibited by a neutralizing anti-IL-6 antibody in preclinical and clinical studies. Further clinical studies of IL-6 antagonists alone or in combination with other therapies are warranted. In view of the antiangiogenic effects reported in this paper and the encouraging results seen with recent GOG218 and ICON-7 studies of bevacizumab, we believe that a randomized trial of siltuximab may be warranted in the maintenance setting.

Disclosure of Potential Conflicts of Interest

J. Nemeth and J. Vermeulen are employees of OrthoBiologics & Oncology. The other authors disclosed no potential conflicts of interest.

Grant Support

This study was funded by the Medical Research Council and siltuximab was provided free by OrthoBiologics & Oncology, Division of Centocor BV, the Netherlands.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 15, 2011; revised July 1, 2011; accepted July 11, 2011; published OnlineFirst July 27, 2011.
References


